


Management options – Reported treatment effectiveness varies with age of initiation, treatment duration, compliance as well as demographic/environmental factors.

Prevention




Slowing progression


Spectacle option




Highly Aspherical Lenslets (HAL)
2 years
 Δ SphE 0.80 D (55%)
 Δ AL 0.35 mm (51%)




Defocus Incorporated Multiple Segments (DIMS)
2 years
 Δ SphE 0.44 D (52%)
 Δ AL 0.34 mm (62%)




Diffusion Optics Technology (DOT)
1 year
 Δ SphE 0.40 D (74%)
 Δ AL 0.15 mm (50%)



Executive Prismatic Bifocals (+1.50 D add)
3 years
 Δ SphE 1.05 D (51%)
 Δ AL 0.28 mm (34%)



Progressive Addition Lens (PALs)
2 years
 Δ SphE 0.14 D (24%)
 Δ AL 0.04 mm (28%)




Peripheral Hyperopia Reduction Lens
2 years
 Δ SphE 0.04 D (3%)
 Δ AL 0.04 mm (5%)

Contact lens option



Dual Focus
3 years
 Δ SphE 0.73 D (59%)
 Δ AL 0.32 mm (52%)
US FDA approved



Extended Depth of Focus
2 years
 Δ SphE 0.37 D (32%)
 Δ AL 0.15 mm (25%)




Center distance (+2.50 D add)
3 years
 Δ SphE 0.46 D (44%)
 Δ AL 0.23 mm (35%)



Orthokeratology
2 years
 Δ AL 0.27 mm (45%)
Worn overnight

Soft contact lenses - worn daily

Pharmacological option



Atropine

0.01%

Δ SphE 0.39 D
 Δ AL 0.13 mm

0.025%

Δ SphE 0.43 D
 Δ AL 0.16 mm


0.05%

Δ SphE 0.62 D
 Δ AL 0.25 mm

Emerging therapies

Combination Atropine (0.01%) and Orthokeratology

2 years
 Δ AL 0.11 mm (27%) compared to Orthokeratology



Red and blue light therapies – safety yet to be established